EMA Withdrawn: Stocrin (efavirenz) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA has withdrawn Stocrin (efavirenz) from the market in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Stocrin (efavirenz)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 14/04/2023